Answers are grounded in this paper and cite their sources.
Patients with low-penetrance NLRP3 variants display a distinct clinical phenotype and an intermediate biologic phenotype, including IL-1β and non-IL-1β-mediated inflammatory pathway activation.
No takes yet. Share an insight, caveat, or question.
Kuemmerle‐Deschner et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: